文献速递艾滋病与性传播感染

HIV-1整合酶抑制剂耐药在脑脊液与血液间无差异

No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究对59例HIV-1患者配对血浆和脑脊液进行整合酶测序,比较整合酶抑制剂耐药突变。结果显示脑脊液与血浆耐药谱相似,仅1例不一致,提示脑脊液耐药可反映血浆情况。

要点

  • 脑脊液与血浆整合酶抑制剂耐药突变谱高度一致。
  • 未治疗者脑脊液耐药突变率33.3%,治疗者25.0%。
  • 临床可参考血浆耐药检测指导中枢神经系统用药。

核心结论

  • 在有病毒血症的HIV-1患者中,脑脊液与血浆的整合酶抑制剂耐药谱相似。

研究设计与样本

  • 对59例HIV-1患者配对血浆和脑脊液进行HIV整合酶测序,并收集临床常规数据。

主要发现

  • 脑脊液整合酶序列耐药突变在未治疗者中为9/27(33.3%),在治疗者中为8/32(25.0%)。
  • 脑脊液耐药突变与血浆相似,仅1/59例患者不一致。
  • 患者主要感染非B亚型(72.2%),最常见重组型为CRF02_AG(42.4%)。
  • 未治疗者血浆HIV-1 RNA中位数5.32 log10 copies/mL,脑脊液4.79 log10 copies/mL。
  • 治疗者血浆HIV-1 RNA中位数3.59 log10 copies/mL,脑脊液3.80 log10 copies/mL。

临床怎么用

  • 对于有病毒血症的HIV-1患者,血浆整合酶耐药检测结果可能反映脑脊液耐药情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about HIV-1 integrase inhibitor resistance in the CNS. OBJECTIVES: This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. METHODS: HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. RESULTS: Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85-5.80) and 3.59 (2.16-4.50) log10 copies/mL versus 4.79 (3.56-5.25) and 3.80 (2.68-4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. CONCLUSIONS: This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Abdi B, Chebbi M, Wirden M, et al. No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. J Antimicrob Chemother. 2021. PMID: 33693680. doi:10.1093/jac/dkab064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。